232
Participants
Start Date
June 24, 2025
Primary Completion Date
March 31, 2027
Study Completion Date
September 30, 2027
Methylprednisolone
Initially, an intravenous dose of 1 mg/kg/day of methylprednisolone will be administered for one week, with the possibility of extending treatment to two weeks if necessary. Following this, participants will receive oral methylprednisolone tablets, starting at a dose of 40 mg/day. The oral dosage will be gradually tapered based on the participants' condition over a period of 1 to 3 months.
Magnesium isoglycyrrhizinate
It is suitable for patients with hepatocellular or mixed DILI. A daily dose of 0.15g to 0.2g
Glutathione
It is suitable for patients with hepatocellular or mixed DILI. A daily dose of 1.2g to 1.8g
Silymarin
It is suitable for patients with hepatocellular or mixed DILI. The dosage is 140 mg, taken 2 to 3 times per day.
Polyene Phosphatidylcholine
It is suitable for patients with hepatocellular or mixed DILI. The dosage is 228mg-456mg, taken 3 times per day.
Ursodeoxycholic acid capsules
It is suitable for patients with cholestatic or mixed DILI. A daily dose of 10mg-15mg/kg/day.
Ademetionine 1,4-Butanedisulfonate
It is suitable for patients with cholestatic or mixed DILI. A daily dose of 0.5g to 1g.
Plaslna exchange
It is suitable for patients whose condition continues to worsen or even develop to liver failure.
Liver transplantation
It is suitable for patients whose condition continues to worsen or even develop to liver failure.
RECRUITING
Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area), Shenyang
General Hospital of Shenyang Military Region
OTHER